This article retrospectively reviews patients receiving prasugrel versus clopidogrel in the TRITON trial. It shows that there was slightly more blood loss and platelet transfusion in those who had received prasugrel, but no difference in mortality.
– Beverley J. Hunt
NATA: Network for the advancement of Patient Blood Manegement, Haemostasis and Thrombosis
MISSION: Providing a multidisciplinary forum for dialogue between haematologists, transfusion medicine specialists, anaesthesiologists, intensive care and emergency physicians, surgeons, perfusionists, nurses, biomedical scientists and ther heathcare professionals.
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.